StockNews.AI
ATYR
StockNews.AI
5 mins

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of aTyr Pharma, Inc. - ATYR

1. Pomerantz LLP is investigating ATYR for potential securities fraud. 2. ATYR's Phase 3 trial results for efzofitimod failed primary endpoints. 3. Stock price dropped 83.25% to $1.01 following trial announcement. 4. Investors are encouraged to join the class action investigation. 5. Pomerantz has a history of handling securities class actions successfully.

3m saved
Insight
Article

FAQ

Why Very Bearish?

The significant price drop after the failed trial indicates strong investor sentiment against ATYR.

How important is it?

The article details legal investigations and failed trials, critical for investor confidence.

Why Short Term?

Immediate negative sentiment may prevail short-term, but future developments could change outlook.

Related Companies

NASDAQ: ATYRNASDAQ: CLDXNASDAQ: AMGN
NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  aTyr Pharma, Inc. (“aTyr” or the “Company”) (NASDAQ: ATYR).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether aTyr and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On September 15, 2025, aTyr issued a press release “announce[ing] topline results from the Phase 3 EFZO-FIT™ study of efzofitimod in 268 patients with pulmonary sarcoidosis, a major form of interstitial lung disease.” The press release disclosed, in relevant part, that the trial had failed to meet its primary endpoint. On this news, aTyr’s stock price fell $5.02 per share, or 83.25%, to close at $1.01 per share on September 15, 2025. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT:Danielle PeytonPomerantz LLPdpeyton@pomlaw.com646-581-9980 ext. 7980

Related News